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ABSTRACT
Background: Increased lipolysis in obese patients will cause elevated free-fatty acid level leading to insulin 
resistance. There are varied inflammatory cytokines (sTNFαR2) and anti-inflammatory cytokines (adiponectin) 
in obese patients, with and without fatty liver (FL). The aim of this study was to determine sTNFαR2 and 
adiponectin levels in obese patients with and without fatty liver.
Method: This study was an observational study with cross-sectional approach, which was conducted 
between September 2008 and August 2009. The patients were 94 obese male with waist circumference ≥ 90 cm 
based on criteria of the International Diabetes Federation. Fatty liver was detected by ultrasonography; while 
adiponectin and sTNFαR2 levels in blood were analyzed by using ELISA method and blood examination at the 
clinical laboratory. 
Results: Levels of adiponectin and sTNFαR2 were different between obese patients with and without FL. 
The adiponectin level was 3.10 ± 1.14 in patients with FL and was 3.52 ± 1.07 in patients without FL; while the 
sTNFαR2 were 23.92 ± 6.00 (FL) and 20.61 ± 5.29 (without FL). In patients with low adiponectin level (< 3.33 
µg/L) and high sTNFαR2 level (> 21.78 pg/dL), there was relatively higher occurrence of fatty liver compared 
to the other patients. 
Conclusion: Obese patients with fatty liver have higher sTNFαR2 level than patients without fatty liver. 
Moreover, obese patients with fatty liver have lower adiponectin level compared to patients without fatty liver. 
Patients with low adiponectin level and high sTNFαR2 level have higher incidence of fatty liver than subjects 
with high adiponectin level and low sTNFαR2 level.
Keywords: adiponectin, soluble tumor necrosis factor α receptor 2 (sTNFαR2), obese, fatty liver
ABSTRAK
Latar Belakang: Lipolisis yang meningkat pada pasien dengan obesitas akan meningkatkan kadar asam 
lemak bebas dan menyebabkan resistensi insulin. Sitokin inflamasi (sTNFαR2) dan sitokin anti-inflamasi 
(adiponektin) bervariasi pada pasien obesitas dengan dan tanpa perlemakan hati (PH). Tujuan penelitian ini 
adalah menentukan kadar sTNFαR2 dan adiponektin pada pasien obesitas dengan dan tanpa perlemakan hati.
Metode: Desain penelitian ini adalah studi observasi dengan pendekatan potong lintang pada bulan 
September 2008 – Agustus 2009. Subjek penelitian yaitu pasien laki-laki obesitas sebanyak 94 orang dengan 
lingkar pinggang ≥ 90 cm (kriteria International Diabetes Federation untuk orang Asia). Perlemakan hati 
dideteksi dengan ultrasonografi. Kadar adiponektin dan sTNFαR2 darah dianalisis menggunakan metode ELISA. 
Pemeriksaan darah dilakukan di laboratorium klinik. 
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INTRODUCTION
Fatty liver is a condition characterized by steatosis 
hepatis or fat accumulation in liver cells, which occur as 
excessive amounts of triglycerides and other fats inside 
the liver cells caused by imbalance between triglycerides 
production and secretion by the liver.1 Fatty liver may 
develop into steatohepatitis, liver fibrosis and liver 
cancer which is usually initiated by steatosis hepatitis.2 
The condition of steatosis hepatis is categorized into 
marcovesicular and microvesicular steatosis.3 The 
prevalence of fatty liver in obese patients ranges from 
25% to 90%; while in diabetic patients, it ranges from 
21 to 55% and 3 to 92% in patients with dyslipidemia.4 
A study conducted by Hasan et al, found 30% prevalence 
of fatty liver in Indonesia.5 The causes of fatty liver 
include alcoholic and non-alcoholic etiologies. One of 
the non-alcoholic causes is obesity. Fatty liver caused 
by obesity has been known as the non-alcoholic fatty 
liver disease (NAFLD).2
The correlation between fatty liver and obesity could 
be explained by several mechanisms including increased 
free fatty acid level and insulin resistance. Type-2 
diabetes and central obesity have been enormously 
reported in association with both NAFLD and non-
alcoholic steatohepatitis (NASH). Insulin resistance 
is the key component in obesity and has been known 
as the risk factor of NAFLD pathogenesis.6 Liver 
fat accumulation and insulin resistance have been 
correlated to the activity of some cytokines, including 
the adipokine. A study conducted by Dyck et al, in mouse 
models found that resistin and tumor nucleus factor-
alpha (TNF-α) or the adipokine have been implicated in 
impairing insulin sensitivity in rodents; while the other 
adipokines, including leptin and adiponectin increase 
insulin sensitivity in lean and obese rodents. Adiponectin 
and leptin have each been demonstrated to increase the 
rate of fatty acid oxidation and decrease muscle lipid 
content, which may become the underlying mechanism 
in improving the insulin effect.7
Adiponectin plays roles as anti-diabetic, anti-
inflammatory and anti-teratogenic agent. There are 
significantly reduced plasma adiponectin levels in 
subjects with obesity, insulin resistance, metabolic 
syndrome, type-2 diabetes and coronary heart disease.8 
Plasma adiponectin concentration was found lower 
in patients with obesity compare to the non-obese 
patients. The underlying mechanism for reduced plasma 
adiponectin concentration is still vague, but one of them 
may include inhibition of TNF-α synthesis and secretion, 
which is produced locally in large amount in visceral 
obesity. It is initiated by macrophage invasion into adipose 
tissue.9,10 Thus, based on such principles, we would like to 
conduct a study to recognize the occurrence of fatty liver 
in obese patients through the interaction of balanced work 
of adiponectin and soluble TNF α receptor 2 (sNFαR2). 
METHOD
This study was an observational study with cross-
sectional approach. The study subjects were adult 
male patients who had their general medical check-
up at Prodia clinical laboratory in Makassar between 
September 2008 and August 2009. Female patients 
were excluded as study subjects to prevent the effect 
of women’s hormone on the adiponectin levels. The 
number of sample that required for the differential 
test was 24 patients per group with 80% of power and 
significance level of (α) 5%; while for the correlation 
test, about 65 patients were required. Of 120 patients, 
94 patients were eligible who were categorized further 
into 2 groups, i.e 49 obese patients with fatty liver and 
45 obese patients without fatty liver. 
The criteria of obesity were determined based on 
the International Diabetes Federation (IDF) for Asian 
population, i.e. male patients would be categorized 
as obese if their waist circumferences were ≥ 90 cm. 
Fatty liver was identified through ultrasonographic 
examination using Medison SA-606® ultrasonography 
(Medison Co LTD, Korea); the criteria for ultrasound 
Hasil: Kadar adiponektin dan sTNFαR berbeda antara pasien dengan obesitas dan tanpa perlemakan 
hati. Kadar adiponektin pada  pasien sebesar 3,10 ± 1,14 (PH) dan 3,52 ± 1,07 (tanpa PH), sedangkan kadar 
sTNFαR2 sebesar 23,92 ± 6,00 (PH) dan 20,61 ± 5,29 (tanpa PH). Pada pasien dengan kadar adiponektin 
rendah (< 3,33 µg/L) dan kadar sTNFαR2 tinggi (> 21,78 pg/dL) kejadian perlemakan hati ditemukan lebih 
tinggi dibanding yang lainnya. 
Kesimpulan: Pasien obesitas dengan perlemakan hati mempunyai kadar sTNFαR2 lebih tinggi dibandingkan 
dengan pasien tanpa perlemakan hati. Disisi lain pada pasien obesitas dengan perlemakan hati mempunyai 
kadar adiponektin yang rendah dibandingkan dengan tanpa perlemakan hati. Pasien dengan kadar adiponektin 
yang rendah dan kadar sTNFαR2 tinggi mengalami kejadian perlemakan hati lebih tinggi dibandingkan dengan 
kadar adiponektin yang tinggi dan sTNFαR2 rendah.
Kata kunci: adiponektin, soluble tumor necrosis factor α receptor 2 (sTNFαR2), obesitas, perlemakan hati
The Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy4
Agus Sulaeman, Syarifuddin Wahid, Ali Sulaiman, Gatot Susilo Lawrence
Table 1. Clinical and biochemical patient characteristics
Parameter Minimum Maximum Mean ± SD
Age (years) 30.00 84.00 43.00 ± 10.00
Waist circumference (cm) 90.00 121.00 99.00 ± 7.00
Systolic blood pressure (mmHg) 90.00 130.00 114.00 ± 9.00
Diastolic blood pressure (mmHg) 70.00 90.00 79.00 ± 4.00
Fasting blood glucose (mg/dL) 77.00 133.00 94.00 ± 11.00
Insulin (mU/mL) 1.99 38.60 8.27 ± 6.45
HOMA IR (mmolμg/MI dL) 0.39 8.86 1.98 ± 1.68
sTNFαR2 level (pg/mL) 12.19 39.99 22.33 ± 5.88
Adiponectin level (µg/mL) 1.07 7.60 3.30 ± 1.12
HOMA IR: homeostatis model assesment of insulin resistance
diagnosis of fatty liver were homogenously increased 
echogenicity and deep posterior attenuation of the 
beam. The inclusion criteria were male aged ≥ 30 
years, obese patient with fatty liver, obese patient 
without fatty liver, non-alcoholic patients, had no 
consumption of 3-hydroxy-3-methyl-glutaryl-CoA 
(HMG-CoA) reductase agents, angiotensin converting 
enzyme (ACE) inhibitor, angiotensin receptor blocker 
(ARB), aspirin; were not undergoing any treatment 
to prevent bias due to the inflammatory drugs effect. 
Moreover, the exclusion criteria were hsCRP level > 
10 mg/L indicating chronic inflammation, including 
the obesity; patients with hepatitis B and C; patients 
who had blood glucose level of > 126 mg/dL, which 
had been determined to reduce the inflammatory factor, 
restricting only from obesity cause; and patients who 
were on diet program for losing their weight, with or 
without drug treatment. 
Adiponectin levels were measured in the fasting 
serum sample through the Sandwich ELISA method by 
using Daiichi Sekisui® reagent (lot number 004RKCED 
2006-06, Japan). sTNFαR2 levels were evaluated in 
the fasting serum sample through Sandwich ELISA 
method by using reagent of Quantikine®catalog 
(number DRT 200; R&D system Inc).
The study has been approved by the Ethics 
Committee of Faculty of Medicine, University of 
Hasanuddin, Makassar. The statistics were performed 
using SPSS software version 16.0 for Windows. 
The statistic test performed were univariate analysis 
including the frequency distribution test and bivariate 
analysis. To observe the patient characteristics with 
and without fatty liver, the frequency distribution 
test was performed in each group. To recognize 
differences between two groups, we performed Mann 
Whitney U test; while to evaluate the correlation 
between variables, we performed the Spearman test. 
Moreover, cross-tabulation was performed to evaluate 
the correlation between adiponectin and sTNFαR2 
levels. Subsequently, we obtained OR value indicating 
the prevalence of fatty liver. The cut-off points for 
adiponectin and sTNFαR2 level were determined based 
on median value of the obtained data with significance 
level of (α) 5%.
RESULTS 
Of 94 eligible male obese patients, the patients were 
categorized into two groups, i.e. 49 male obese patients 
with fatty liver and 45 male obese patients without 
fatty liver. The general characteristics of patients are 
presented on Table 1; while the characteristics of both 
groups could be seen on Table 2. 
On Table 2, we present characteristics of age, 
systolic and diastolic blood pressure and no significant 
difference between both groups. Waist circumference, 
fasting blood glucose level, insulin level, homeostatic 
model assessment of insulin resistance (HOMA 
IR), sTNFαR2 were significantly higher in the fatty 
Table 2. Clinical and biochemical characteristics in fatty liver and non-fatty liver groups 
Parameter Fatty liver (mean ± SD)
Non-fatty liver
(mean ± SD) p*
Age (years) 42.00 ± 9.00 44.00 ± 11.00 0.527
Waist circumference (cm) 101.00 ± 8.00 95.00 ± 5.00 0.000
Systolic blood pressure (mmHg) 113.00 ± 8.00 115.00 ± 9.00 0.299
Diastolic blood pressure (mmHg) 80.00 ± 3.00 78.00 ± 5.00 0.169
Fasting blood glucose (mg/dL) 95.00 ± 11.00 91,00 ± 10.00 0.048
Insulin (mU/mL) 10.39 ±7.49 5.97 ± 4.04 0.000
HOMA IR (mmolμg/MI dL) 2.55 ± 2.00 1.35 ± 0.92 0.000
sTNFαR2 level (pg/mL) 23.90 ± 6.00 20.61 ± 5.29 0.004
Adiponectin level (µg/mL) 3.10 ± 1.14 3.52 ± 1.07 0.050
HOMA IR: homeostatis model assesment of insulin resistance; * Mann Whitney U test
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relatively important role of inflammation may affect 
the process of developing inflammation itself. This 
study also demonstrated the dynamic features of 
adiponectin and sTNFαR2 levels; while the distribution 
of adiponectin and sTNFαR2 levels could be seen on 
Figure 1. The figure shows that some patients with 
low adiponectin levels apparently also have higher 
sTNFαR2 level. Figure 1 also implies that incidence 
of fatty liver is more highly distributed in patients with 
low adiponectin and TNFαR2 levels.
The dynamic properties between adiponectin and 
sTNFαR2 were tested by determining the cut off point 
of each parameter. The cut off value of adiponectin level 
was determined at 3.33 µg/mL (≥ 3.33 µg/mL = high 
adiponectin level; < 3.33 µg/mL = low adiponectin level); 
while the cut off value of sTNFαR2 level was 21.98 pg/
mL (< 21.78 pg/mL = low sTNFαR2 level, ≥ 21.78 pg/mL 
= high sTNFαR2 level). This study results demonstrated 
that there was higher occurrence of fatty liver on conditions 
Table 3. The correlation between fatty liver and some parameters
Parameter r p*
Control
WC WC, FBG, insulin, HOMA IR                           
r p* r p*
Waist circumference (cm) -0.409 0.000
FBG (mg/dL) -0.109 0.067 -0.122 0.242
Insulin (mU/mL) -0.344 0.001 -0.241 0.020
HOMA IR (mmolμg/MI dL) -0.358 0.000 -0.252 0.015
sTNFαR2 (pg/mL) -0.282 0.006 -0.216 0.038 -0.251 0.017
Adiponectin (µg/mL) 0.188 0.070 0.190 0.068 0.120 0.259
WC: waist circumference; FBG: fasting blood glucose; HOMA IR= homeostatis model assesment of insulin resistance; r = 
correlation; * Spearman correlation test
liver group compared to the non-fatty liver group. 
Adiponectin level in fatty liver group was significantly 
lower than the non-fatty liver group. 
The correlation of variables to incidence of fatty 
liver and the partial correlation in controlling waist 
circumference, blood glucose level, insulin and HOMA 
IR to evaluate the independency of those parameters to 
the incidence of fatty liver could be seen on Table 3.
The Table 3 shows that waist circumference, 
HOMA IR and sTNFαR2 have negative correlation to 
the non-occurrence of fatty liver, which means that low 
value of waist circumference, HOMA IR and sTNFαR2 
plays role in the non-occurrence of fatty liver; while 
adiponectin has positive correlation indicating that 
high adiponectin level has important role in the non-
occurrence of fatty liver. 
Table 3 also demonstrates that sTNFαR2 is 
independent factor that affect the occurrence of fatty 
liver in this study. Such condition indicates that a 
Figure 1. Distribution of adiponectin level on sTNFαR2 level
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of adiponectin level < 3.33 µg/mL and sTNFαR2 level ≥ 
21.78 compared to other condition with adiponectin level 
≥ 3.33 µg/mL and sTNFαR2 < 21.78 pg/mL (Figure 2). 
Dynamic characteristics between adiponectin and 
sTNFαR2 levels could be observed by performing the 
cross tabulation test on the dynamics of those levels 
with the occurrence of fatty liver (Table 4) . This study 
results demonstrated significant correlation (p > 0.001) 
between the dynamic characteristics of adiponectin as 
well as sTNFαR2 and the occurrence of fatty liver with 
OR 6.43 (95% CI = 1.932–21.389) indicating that the 
occurrence of fatty liver in obese patients increased by 
normal cell which will develop into steatorrhoeic cell, 
steatohepatitis and liver fibrosis. Such progressivity 
will be followed by varied adipokines produced by 
adipocytes. The adipokines will be further involved in 
the fatty liver process including adiponectin as anti-
inflammatory agent and TNF as the pro-inflammatory 
agents. 
Adiponectin, an anti-inflammatory adipocytokine, 
may modulate the insulin effect. Adiponectin is a protein 
with 30 kDa molecular weight. In normal subject, the 
expression of adiponectin is limited to adipose tissue. 
Adiponectin level has negative correlation with body 
mass index (BMI), blood glucose level, fasting insulin 
level, insulin resistance and triglycerides.14
This study found lesser occurrence of fatty liver 
compared to non-fatty liver (Table 2). This study has 
been relevant to the study conducted by Yoon et al, 
which demonstrated that hypoadiponectinemia may 
occur in individuals with NAFLD. The experimental 
studies have demonstrated that adiponectin has 
protective effect both against alcohol and NAFLD. 
Yoon et al study has reported that hypoadiponectinemia 
is a feature of NASH independent of insulin resistance 
and lower adiponectin level is associated with 
the amount of necroinflammation and may have 
contribution on the development of necroinflammation 
in NAFLD.14
sTNFαR2 is a stable protein, which have been 
studied to be associated with BMI, waist hip ratio 
and insulin resistance; therefore, it could be used as 
a better predictor to demonstrate the activation of local 
TNF α system compared to the concentration of TNF- 
α in blood.15 This study found that there were higher 
sTNFαR2 levels in patients with fatty liver than without 
fatty liver. It may be caused by the compensatory 
process in the body due to the low anti-inflammatory 
adipokines produced by lesser adipocytes number. 
Adiponectin and TNF α may inhibit each other, 
which indicate that both adipocytokines have 
interaction in different metabolic pathway. A study 
by Kirsch et al, demonstrated that there were reduced 
adiponectin levels, increased soluble TNF receptor 2 
levels in patients with NASH compared to the control 
group.16
TNF-α suppresses the transcription of 3T3-L1 
in adipocytes, which is the basic mechanism of low 
adiponectin level in obese patients. A study conducted 
by Shimomura et al showed that in mouse models, the 
adiponectin characterized by high expression of TNF 
mRNA in adipose tissue and high TNF plasma level.17
On the other hand, the anti-inflammatory effect 
of adiponectin may inhibit the TNF regulation in 
affecting the expression of adhesion molecules on 
endothelial cells. Adiponectin inhibits the signaling 
endothelial nuclear factor kappa-β (NF-қβ) through 
Table 4. Correlation between varied adiponectin and sTNFαR2 level 
on the occurrence of fatty liver 
Fatty liver
n (%)
Non-fatty liver
n (%) p* OR*
Low adiponectin level (μg/mL), 
High TNFR2 level (pg/mL) 24 (44) 7 (13) 0.002 6.43
High adiponectin level (μg/mL), 
Low sTNFR2 level ( pg/mL) 8 (15) 15 (28) 0.002
OR: odds ratio; *chi square test
Figure 2. Percentage of fatty liver and non-fatty liver occurrence 
in different levels of adiponectin and soluble tumor necrosis 
factor α receptor 2
6.43 fold higher in patients who had low adiponectin 
level and high sTNFα2 level, compared to patients 
with high adiponectin level and low sTNFαR2 level.
DISCUSSION
NAFLD is defined as a condition of steatorrhoeic 
liver on individual without alcohol intake yet still had 
liver injury. Although some drugs or genetic disorder 
may cause NAFLD, but the main causes in almost all 
cases include obesity, insulin resistance and type-2 
diabetes.11,12
A study by Sulaeman et al, demonstrated that 
50% of obesity patients and 66% patients with 
metabolic syndrome also experienced fatty liver.13 
The progressivity of fatty liver may occur from the 
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cyclic 3’,5’-adenosine monophosphate, which may 
affect the macrophage function. The study conducted 
by Shimamura et al demonstrated that macrophage 
cultured with adiponectin had significantly inhibited 
the TNF synthesis as a response against endotoxin. 
The mouse model with adiponectin level showed 
increased production of both local and systemic TNF. 
It was assumed because of the suppressive effect of 
adiponectin on the synthesis and expression of TNF.18
Dynamic characteristics between anti-inflammatory 
cytokines and inflammatory cytokines may be 
illustrated by observing the adiponectin and sTNFαR2 
levels. On Table 4, this study shows that the adiponectin 
level in obese patients with fatty liver is lower than 
patients without fatty liver. Moreover, the sTNFαR2 
level is higher in obese patients with fatty liver 
compared to non-fatty liver patients. In this case, the 
dynamic characteristics of adiponectin and TNF α 
includes sTNFαR2 showing alteration of inflammatory 
condition and reduced anti-inflammatory agent will 
develop higher occurrence of fatty liver; therefore, it 
can be assumed that the balance between inflammatory 
and anti-inflammatory agents may have important role 
in the development of fatty liver. 
This study suggests the importance of considering 
balance between inflammatory and anti-inflammatory 
condition in obese patients to prevent the risk of 
developing fatty liver. We also expect that this study 
may enhance the basic approach of treatment for fatty 
liver by taking inflammatory condition into account 
in obese patients. 
The weakness of this study includes the utilization 
of ultrasonography for detecting fatty liver which 
could not illustrate the cellular situation during the 
study. Further studies should be conducted based on 
the results of this study including the more sensitive 
detection for fatty liver which may provide more 
obvious evidence of clinical condition. 
CONCLUSION
There are reduced adiponectin level and increased 
sTNFαR2 level in obese patients who also have fatty 
liver. Such condition will also increase the occurrence 
of fatty liver. 
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